Fluor Corporation (NYSE:FLR) said yesterday that it landed a contract to build Novo Nordisk‘s (NYSE:NVO) $2 billion diabetes active pharmaceutical ingredient manufacturing facility in Clayton, North Carolina. Since Denmark-based Novo Nordisk announced plans for the facility in August 2015, Fluor has been providing basic design services for the project.
The manufacturing facility will measure 830,000 square feet and provide approximately 700 new jobs when it is complete. At peak construction, the project will bring on board almost 2,500 craft employees and subcontractors. Irving, Texas-based Fluor said it anticipates that construction for the project will finish in mid-2019.
Get the full story at our sister site, Medical Design & Outsourcing.
